Modeling lesion counts in multiple sclerosis when patients have been selected for baseline activity
暂无分享,去创建一个
G R Cutter | C. Morgan | C R Katholi | C J Morgan | I B Aban | G. Cutter | IB Aban | CR Katholi
[1] M. Filippi,et al. Statistical Issues Related to the Use of MRI Data in Multiple Sclerosis , 2007, Journal of neuroimaging : official journal of the American Society of Neuroimaging.
[2] F. Barkhof,et al. Statistical power of MRI monitored trials in multiple sclerosis: new data and comparison with previous results , 1999, Journal of neurology, neurosurgery, and psychiatry.
[3] Robert J. Temple,et al. Special study designs: early escape, enrichment, studies in non-responders , 1994 .
[4] G. Comi,et al. Modelling new enhancing MRI lesion counts in multiple sclerosis , 2001, Multiple sclerosis.
[5] M. Filippi,et al. The distribution of the magnetic resonance imaging response to glatiramer acetate in multiple sclerosis , 2005, Multiple sclerosis.
[6] A. Thompson,et al. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis patients: Statistical power of parallel-groups and crossover designs , 1994, Journal of the Neurological Sciences.
[7] H. Akaike. A new look at the statistical model identification , 1974 .
[8] F. Barkhof,et al. Modelling MRI enhancing lesion counts in multiple sclerosis using a negative binomial model: implications for clinical trials , 1999, Journal of the Neurological Sciences.
[9] C. Granger,et al. Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis , 1996, Annals of neurology.
[10] Roland Martin,et al. Using gadolinium‐enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis , 1992, Annals of neurology.
[11] G Cutter,et al. Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS , 2001, Neurology.
[12] Massimo Filippi,et al. European/Canadian multicenter, double‐blind, randomized, placebo‐controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosis , 2001, Annals of neurology.
[13] F. Barkhof,et al. Clinical trials of multiple sclerosis monitored with enhanced MRI: new sample size calculations based on large data sets , 2001, Journal of neurology, neurosurgery, and psychiatry.
[14] A. Thompson,et al. The distribution of magnetic resonance imaging response to interferonβ–1b in multiple sclerosis , 2005, Journal of Neurology.
[15] F Barkhof,et al. The distribution of new enhancing lesion counts in multiple sclerosis: further explorations , 2009, Multiple sclerosis.
[16] Inmaculada B. Aban,et al. Inferences and power analysis concerning two negative binomial distributions with an application to MRI lesion counts data , 2009, Comput. Stat. Data Anal..